Koen Poesen

4.5k total citations
69 papers, 1.4k citations indexed

About

Koen Poesen is a scholar working on Molecular Biology, Neurology and Physiology. According to data from OpenAlex, Koen Poesen has authored 69 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 24 papers in Neurology and 19 papers in Physiology. Recurrent topics in Koen Poesen's work include Alzheimer's disease research and treatments (18 papers), Amyotrophic Lateral Sclerosis Research (14 papers) and Dementia and Cognitive Impairment Research (11 papers). Koen Poesen is often cited by papers focused on Alzheimer's disease research and treatments (18 papers), Amyotrophic Lateral Sclerosis Research (14 papers) and Dementia and Cognitive Impairment Research (11 papers). Koen Poesen collaborates with scholars based in Belgium, United States and Netherlands. Koen Poesen's co-authors include Philip Van Damme, Kristl G. Claeys, Maxim De Schaepdryver, Rik Vandenberghe, Benjamin Gille, Jolien Schaeverbeke, Ludo Van Den Bosch, Xavier Bossuyt, Lieselot Dedeene and Jos Tournoy and has published in prestigious journals such as Circulation, Brain and Neurology.

In The Last Decade

Koen Poesen

65 papers receiving 1.4k citations

Peers

Countries citing papers authored by Koen Poesen

Since Specialization

Citations

This map shows the geographic impact of Koen Poesen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koen Poesen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koen Poesen more than expected).

Fields of papers citing papers by Koen Poesen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koen Poesen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koen Poesen. The network helps show where Koen Poesen may publish in the future.

Co-authorship network of co-authors of Koen Poesen

This figure shows the co-authorship network connecting the top 25 collaborators of Koen Poesen. A scholar is included among the top collaborators of Koen Poesen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koen Poesen. Koen Poesen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Serum biomarkers as prognostic markers for Alzheimer's disease in a clinical setting 2025 ·Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring ·Steffi De Meyer, (unknown), Jolien Schaeverbeke, Katarzyna Adamczuk, Rik Vandenberghe, Koen Poesen, Charlotte E. Teunissen	2
2	Exploiting the role of CSF NfL, CHIT1, and miR-181b as potential diagnostic and prognostic biomarkers for ALS 2024 ·Journal of Neurology ·Delia Gagliardi, Mafalda Rizzuti, Pegah Masrori, (unknown), Roberto Del Bo, (unknown), Megi Meneri, Simone Scarcella, (unknown), Nicole Hersmus, (unknown), (unknown), Vincenzo Silani, Koen Poesen, Philip Van Damme, Giacomo P. Comi, Stefania Corti, Federico Verde	3
3	Are inflammatory markers associated with sarcopenia-related traits in older adults with sarcopenia? – A cross-sectional analysis of the ENHANce study 2023 ·Experimental Gerontology ·Jolan Dupont, (unknown), (unknown), (unknown), Maxim De Schaepdryver, Koen Poesen, Lenore Dedeyne, Sabine Verschueren, Jos Tournoy, Katrien Koppo, Evelien Gielen	18
4	Performance of plasma pTau181 and pTau217 measured with fully automated LUMIPULSE G prototype immunoassays 2023 ·Alzheimer s & Dementia ·Jeroen Vanbrabant, Steffi De Meyer, (unknown), (unknown), (unknown), (unknown), Carrie E. Rubel, Julie Czerkowicz, Kyle Fraser, Danielle Graham, (unknown), Katsumi Aoyagi, Eugeen Vanmechelen, Koen Poesen, Rik Vandenberghe, Erik Stoops	1
5	Effect of neurofilament analysis on the diagnostic delay in amyotrophic lateral sclerosis 2022 ·CNS Neuroscience & Therapeutics ·Maxim De Schaepdryver, Pegah Masrori, Philip Van Damme, Koen Poesen	4
6	Biochemical and clinical biomarkers in adult SMA 3–4 patients treated with nusinersen for 22 months 2022 ·Annals of Clinical and Translational Neurology ·(unknown), Maxim De Schaepdryver, Koen Poesen, Kristl G. Claeys	30
7	Detection of multiple myositis-specific autoantibodies in unique patients with idiopathic inflammatory myopathy: A single centre-experience and literature review 2021 ·Seminars in Arthritis and Rheumatism ·(unknown), Jean‐Baptiste Vulsteke, Xavier Bossuyt, Kristl G. Claeys, (unknown), Koen Poesen, (unknown), Philip Van Damme, Daniël Blockmans, Petra De Haes, Ellen De Langhe	10
8	Dipeptide repeat protein and TDP-43 pathology along the hypothalamic–pituitary axis in C9orf72 and non-C9orf72 ALS and FTLD-TDP cases 2020 ·Acta Neuropathologica ·Lieselot Dedeene, Evelien Van Schoor, Simona Ospitalieri, Alicja Ronisz, Jochen H. Weishaupt, Markus Otto, Albert C. Ludolph, Angelika Scheuerle, Rik Vandenberghe, Philip Van Damme, Koen Poesen, Dietmar Rudolf Thal	9
9	Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis 2020 ·Alzheimer s Research & Therapy ·Steffi De Meyer, Jolien Schaeverbeke, Inge M.W. Verberk, Benjamin Gille, Maxim De Schaepdryver, Emma S. Luckett, Silvy Gabel, Rose Bruffaerts, Kimberley Mauroo, Elisabeth H. Thijssen, Erik Stoops, Hugo Vanderstichele, Charlotte E. Teunissen, Rik Vandenberghe, Koen Poesen	70
10	Clinical spectrum of the anti-GQ1b antibody syndrome: a case series of eight patients 2019 ·Acta Neurologica Belgica ·(unknown), Koen Poesen, Xavier Bossuyt, (unknown), (unknown), Christophe Depuydt, Philip Van Damme, Kristl G. Claeys	12
11	Serum neurofilament heavy chains as early marker of motor neuron degeneration 2019 ·Annals of Clinical and Translational Neurology ·Maxim De Schaepdryver, (unknown), Steffi De Meyer, Andreas Jeromin, Pegah Masrori, Britta Brix, Kristl G. Claeys, Jolien Schaeverbeke, Katarzyna Adamczuk, Rik Vandenberghe, Philip Van Damme, Koen Poesen	35
12	Diagnostic and Prognostic Performance of Neurofilaments in ALS 2019 ·Frontiers in Neurology ·Koen Poesen, Philip Van Damme	91
13	Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? 2019 ·Journal of Neurology Neurosurgery & Psychiatry ·Benjamin Gille, Maxim De Schaepdryver, Lieselot Dedeene, (unknown), Kristl G. Claeys, Ludo Van Den Bosch, Jos Tournoy, Philip Van Damme, Koen Poesen	62
14	Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis 2018 ·Neuropathology and Applied Neurobiology ·Benjamin Gille, Maxim De Schaepdryver, (unknown), Lieselot Dedeene, Joke De Vocht, Emanuela Oldoni, An Goris, Ludo Van Den Bosch, Bart Depreitere, Kristl G. Claeys, Jos Tournoy, Philip Van Damme, Koen Poesen	90
15	Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used 2018 ·Leukemia ·Xavier Bossuyt, Michel Delforge, (unknown), (unknown), Ben Sprangers, Karel Fostier, Koen Poesen, Martine Vercammen	18
16	FRI0393 Prevalence of myositis-specific antibodies in idiopathic inflammatory myopathy compared to disease and healthy controls 2017 ·Annals of the Rheumatic Diseases ·(unknown), Xavier Bossuyt, (unknown), Koen Poesen, Kristl G. Claeys, (unknown), René Westhovens, Daniël Blockmans, Petra De Haes, Ellen De Langhe	1
17	A case report of an atypical POEMS syndrome 2015 ·(unknown), Dirk De Ruysscher, Koen Poesen, Olivier Gheysens, (unknown), Michel Delforge	1
18	Performance of cassette-based blood gas analyzers to monitor blood glucose and lactate levels in a surgical intensive care setting 2013 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·Koen Poesen, (unknown), Greet Van den Berghe, Johan Van Eldere, Florent Vanstapel	7
19	Neuronal FLT1 receptor and its selective ligand VEGF‐B protect against retrograde degeneration of sensory neurons 2011 ·The FASEB Journal ·Joke Dhondt, Eve Peeraer, An Verheyen, Rony Nuydens, Ian Buysschaert, Koen Poesen, Katie Van Geyte, Manu Beerens, Masabumi Shibuya, Jody J. Haigh, Theo Meert, Peter Carmeliet, Diether Lambrechts	45
20	Advantages of the Vegf Inhibitor, Macugen: A More Favourable Toxicity Profile 2008 ·Investigative Ophthalmology & Visual Science ·Koen Poesen, Thierry Janssens, Diether Lambrechts, Peter Carmeliet, Edward M. Conway	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact